Organogenesis Holdings Inc. (ORGO) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↓
4.26
↓-69% vs avg
5yr avg: 13.70
30Y Low8.6·High24.0
P/FCF
↑
N/A
—
5yr avg: 74.64
30Y Low40.2·High100.9
P/B Ratio
↓
0.73
↓-67% vs avg
5yr avg: 2.21
30Y Low1.1·High15.0
ROE
↓
9.0%
↑-32% vs avg
5yr avg: 13.3%
30Y Low-75%·High49%
Debt/EBITDA
↑
1.60
↓-34% vs avg
5yr avg: 2.45
30Y Low1.5·High17.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ORGO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Organogenesis Holdings Inc. trades at 16.3x earnings, 64% below its 5-year average of 45.0x, sitting at the 20th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 26%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $314M | $675M | $421M | $543M | $356M | $1.2B | $839M | $447M | $704M | $634M | — |
| Enterprise Value | $353M | $714M | $329M | $558M | $377M | $1.3B | $839M | $487M | $742M | $651M | — |
| P/E Ratio → | 16.27 | 34.53 | — | 109.65 | 22.42 | 13.20 | 50.20 | — | — | — | — |
| P/S Ratio | 0.56 | 1.20 | 0.87 | 1.25 | 0.79 | 2.64 | 2.48 | 1.71 | 3.64 | — | — |
| P/B Ratio | 0.73 | 1.55 | 1.09 | 1.95 | 1.34 | 5.12 | 5.91 | 8.03 | 14.96 | 2.13 | — |
| P/FCF | — | — | 100.90 | 82.85 | — | 40.15 | — | — | — | — | — |
| P/OCF | — | — | 29.66 | 17.56 | 14.33 | 19.93 | 153.41 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ORGO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Organogenesis Holdings Inc.'s enterprise value stands at 4.3x EBITDA, 69% below its 5-year average of 13.7x. The Healthcare sector median is 14.2x, placing the stock at a 70% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.27 | 0.68 | 1.29 | 0.84 | 2.68 | 2.48 | 1.87 | 3.83 | — | — |
| EV / EBITDA | 4.26 | 8.62 | 20.90 | 15.51 | 9.36 | 14.10 | 24.05 | — | — | 628.65 | — |
| EV / EBIT | 6.32 | 12.78 | — | 44.34 | 16.93 | 17.82 | 28.89 | — | — | — | — |
| EV / FCF | — | — | 78.81 | 85.14 | — | 40.75 | — | — | — | — | — |
ORGO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Organogenesis Holdings Inc. earns an operating margin of 9.9%. Operating margins have expanded from 2.9% to 9.9% over the past 3 years, signaling improving operational efficiency. ROE of 9.0% is modest. ROIC of 10.9% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.6% | 75.6% | 76.0% | 75.4% | 76.7% | 75.6% | 74.2% | 70.9% | 64.4% | — | — |
| Operating Margin | 9.9% | 9.9% | -0.3% | 2.9% | 4.9% | 15.5% | 7.9% | -11.4% | -26.7% | — | — |
| Net Profit Margin | 6.6% | 6.6% | 0.2% | 1.1% | 3.4% | 20.2% | 5.1% | -14.8% | -33.5% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 9.0% | 9.0% | 0.3% | 1.8% | 6.1% | 49.2% | 17.5% | -75.4% | -37.6% | -0.7% | -0.1% |
| ROA | 6.8% | 6.8% | 0.2% | 1.1% | 3.5% | 25.7% | 6.7% | -20.1% | -27.2% | -0.7% | -0.1% |
| ROIC | 10.9% | 10.9% | -0.3% | 3.2% | 6.1% | 27.0% | 16.8% | -24.7% | -19.3% | -1.1% | 0.1% |
| ROCE | 12.2% | 12.2% | -0.3% | 3.3% | 6.1% | 24.8% | 14.0% | -23.1% | -25.4% | -1.5% | 0.1% |
ORGO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Organogenesis Holdings Inc. carries a Debt/EBITDA ratio of 1.6x, which is manageable (50% below the sector average of 3.2x). Net debt stands at $39M ($133M total debt minus $94M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.31 | 0.31 | 0.11 | 0.43 | 0.47 | 0.55 | 0.60 | 1.81 | 1.26 | 0.06 | — |
| Debt / EBITDA | 1.60 | 1.60 | 2.75 | 3.32 | 3.07 | 1.49 | 2.43 | — | — | 17.24 | — |
| Net Debt / Equity | — | 0.09 | -0.24 | 0.05 | 0.08 | 0.08 | 0.00 | 0.73 | 0.81 | 0.06 | -0.00 |
| Net Debt / EBITDA | 0.47 | 0.47 | -5.86 | 0.42 | 0.53 | 0.21 | 0.01 | — | — | 17.11 | — |
| Debt / FCF | — | — | -22.09 | 2.29 | — | 0.60 | — | — | — | — | — |
| Interest Coverage | — | — | -0.82 | 5.75 | 11.10 | 9.72 | 2.57 | -3.29 | -4.97 | -0.82 | -0.04 |
ORGO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Organogenesis Holdings Inc.'s current ratio of 3.62x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.80x to 3.62x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.62 | 3.62 | 3.69 | 2.80 | 2.97 | 2.74 | 2.56 | 2.10 | 1.07 | 0.07 | 3.00 |
| Quick Ratio | 3.32 | 3.32 | 3.35 | 2.44 | 2.64 | 2.44 | 2.15 | 1.71 | 0.87 | 0.07 | 3.00 |
| Cash Ratio | 0.94 | 0.94 | 1.75 | 1.30 | 1.37 | 1.38 | 1.24 | 1.00 | 0.32 | 0.03 | 2.17 |
| Asset Turnover | — | 0.94 | 0.97 | 0.94 | 1.00 | 1.05 | 1.17 | 1.18 | 1.18 | — | — |
| Inventory Turnover | 4.64 | 4.64 | 4.41 | 3.77 | 4.24 | 4.56 | 3.14 | 3.31 | 5.17 | — | — |
| Days Sales Outstanding | — | 140.97 | 83.19 | 69.10 | 72.41 | 64.40 | 61.29 | 55.05 | 64.30 | — | — |
ORGO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Organogenesis Holdings Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 6.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 0.4% | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | 208.8% | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 6.1% | 2.9% | — | 0.9% | 4.5% | 7.6% | 2.0% | — | — | — | — |
| FCF Yield | — | — | 1.0% | 1.2% | — | 2.5% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 6.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.5% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 6.5% | 0.0% | 0.0% | 0.0% | 0.0% | 1.5% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $130M | $132M | $133M | $132M | $134M | $111M | $93M | $69M | $64M | $9M |
Peer Comparison
Compare ORGO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ORGOYou | $314M | 16.3 | 4.3 | — | 75.6% | 9.9% | 9.0% | 10.9% | 1.6 |
 MDXG | $545M | 11.5 | 5.1 | 7.5 | 82.6% | 15.3% | 21.6% | 42.3% | 0.3 |
 NVCR | $2B | -11.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 TELA | $37M | -1.0 | — | — | 67.7% | -42.0% | -223.4% | -169.0% | — |
 APOG | $888M | 16.4 | 24.1 | 9.3 | 22.7% | 6.0% | 10.8% | 8.1% | 6.1 |
 IONS | $12B | -31.1 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 MGRX | $3M | -0.2 | — | — | 54.9% | -4200.5% | -141.7% | -102.2% | — |
 SKIN | $86M | -4.1 | 51.0 | 2.3 | 65.3% | -6.9% | -16.9% | -6.8% | 83.3 |
 XTNT | $62M | 14.7 | 5.9 | 6.1 | 62.9% | 5.4% | 10.6% | 8.1% | 2.3 |
 ANIK | $193M | -19.0 | — | 44.3 | 56.6% | -9.8% | -7.3% | -7.1% | — |
 NAUT | $290M | -4.9 | — | — | — | — | -32.3% | -26.0% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ORGO — Frequently Asked Questions
Quick answers to the most common questions about buying ORGO stock.
What is Organogenesis Holdings Inc.'s P/E ratio?
Organogenesis Holdings Inc.'s current P/E ratio is 16.3x. The historical average is 46.0x. This places it at the 20th percentile of its historical range.
What is Organogenesis Holdings Inc.'s EV/EBITDA?
Organogenesis Holdings Inc.'s current EV/EBITDA is 4.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 15.4x.
What is Organogenesis Holdings Inc.'s ROE?
Organogenesis Holdings Inc.'s return on equity (ROE) is 9.0%. The historical average is -3.0%.
Is ORGO stock overvalued?
Based on historical data, Organogenesis Holdings Inc. is trading at a P/E of 16.3x. This is at the 20th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Organogenesis Holdings Inc.'s profit margins?
Organogenesis Holdings Inc. has 75.6% gross margin and 9.9% operating margin.
How much debt does Organogenesis Holdings Inc. have?
Organogenesis Holdings Inc.'s Debt/EBITDA ratio is 1.6x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.